Kidney cancer drugs have emerged as one of the few life-prolonging treatment regimens for patients in scenarios where surgical treatment alone is insufficient to treat advanced stage renal cancer. Renal cell carcinoma (RCC) and transitional cell carcinoma (TCC) are the two known types of kidney cancer, the former being most common, according to the American Cancer Society.
A report recently published by Transparency Market Research reveals that by 2020, the value of the global kidney cancer drugs market will be US$4.5 billion, rising from US$2.6 billion in 2013 at a steady CAGR of 6.6% during the period.
Discussed below are some of the factors driving the global kidney cancer drugs market.
Browse Market Research Report of Kidney Cancer Drugs Market: http://www.transparencymarketresearch.com/kidney-cancer-drugs-market.html
Rising Incidence of Kidney Cancer
The kidney cancer drugs market owes its growth to the global surge in kidney cancer cases. According to the World Cancer Research Fund International, kidney cancer is the 12th most common cancer in the world, with 338,000 new cases diagnosed in 2012 alone.
The 2015 estimates for kidney cancer in the U.S. by the American Cancer Society indicate that there will be around 61,560 new cases of kidney cancer in the present year, 23,290 in women and 38,270 in men. Of these, an estimated 14,080 people will die from this disease.
The American Cancer Society states that the rate of new kidney cancers has been on the rise since the 1990s. However, the death rates for these cancers have also gone down since that time, mainly owing to newer imaging tests and innovative treatment options.
Increase in Geriatric Population
Studies show that most people with kidney cancer are older and this type of cancer is very uncommon in people below the age of 45. The survival rate of kidney cancer drops with age. Surgery is usually not the best option for older patients with renal cancer as it doubles the patient’s risk of developing heart problems or dying of other causes. Younger people with longer life expectancies have a better chance of survival after surgery. In such cases, drugs and other non-surgical treatment options prove to be the ideal alternative.
Rise in geriatric population across the globe is thus a major factor driving the kidney cancer drugs market.
Browse Market Research Press Release of Kidney Cancer Drugs Market: http://www.transparencymarketresearch.com/pressrelease/kidney-cancer-drugs-market.htm
Surge in Research Activities
There have been constant efforts directed at the development of new kidney cancer drugs that are more effective than existing ones. The list of renal cancer drugs approved by the US FDA is impressive: Everolimus, Temsirolimus, Axitinib, Bevacizumab, Pazopanib Hydrochloride, Torisel (Temsirolimus), Proleukin (Aldesleukin), Votrient (Pazopanib Hydrochloride), Inlyta (Axitinib), Avastin (Bevacizumab), Afinitor (Everolimus), Sorafenib Tosylate, Sutent (Sunitinib Malate), Aldesleukin, Sunitinib Malate, and Nexavar (Sorafenib Tosylate)
Last month, Bristol-Myers Squibb and Exelixis reported impressive results in late-stage clinical trials of metastatic kidney cancer drugs. Cometriq, a medullary thyroid cancer drug marketed by Exelixis, appears to be more effective as a second-line kidney cancer drug than in prostate cancer. The trials showed that Cometriq improved progression-free survival rate for metastatic kidney cancer patients by 42%, as against Novartis’ Affinitor.
Such ground-breaking research activities have made a major contribution toward the growth of the kidney cancer drugs market.